Kura Oncology to Report First Quarter 2024 Financial Results
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing […]
TSX News -
Orezone Intersects 18.41 g/t Gold Over 8.00m and 22.17 g/t Gold Over 4.00m in Ongoing Exploration
VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) […]
Plato Gold Reports on 2023 Year-End Results
Toronto, ON, April 25, 2024 (GLOBE NEWSWIRE) — Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) […]
FTI Consulting Reports Record First Quarter 2024 Financial Results
First Quarter 2024 Revenues of $928.6 Million, Up 15% Compared to $806.7 Million in Prior Year Quarter First Quarter 2024 […]
Jushi Holdings Inc. to Report First Quarter 2024 Financial Results on May 9, 2024
BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), […]
ParaZero Integrates its Safety Technology into Draganfly’s Commander 3XL Drones for Home Hospital Delivery and Emergency Response
Tel Aviv, Israel, April 25, 2024 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “Company” or “ParaZero”), an aerospace […]
Draganfly Integrates ParaZero Safety Technology into Commander 3XL Drones for Home Hospital Delivery and Emergency Response
San Diego, CA., April 25, 2024 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the […]
EnviroGold Global to Build Demonstration Plant in Brisbane, Australia
TORONTO, April 25, 2024 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold,” “NVRO,” […]
Altisource Announces First Quarter 2024 Financial Results
LUXEMBOURG, April 25, 2024 (GLOBE NEWSWIRE) — Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider […]
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with […]
